The phase 2 study of the Dgat2 selective inhibitor ervogastat (PF-06865571) co-administered with clesacostat in NAFLD patients has been completed with satisfactory results (NCT03776175).60 This evidence concerns the gene DGAT2 and metabolic dysfunction-associated steatotic liver disease.